THT 2025 Conference to Showcase Groundbreaking Heart Failure Clinical Trials
核心洞察
The Cardiovascular Research Foundation's Technology & Heart Failure (搜索) Therapeutics (THT) 2025 conference will feature multiple late-breaking clinical trials across four dedicated sessions.
Key studies include novel treatments such as robotic heart transplant techniques, interatrial shunting for different types of heart failure (搜索), and innovative fluid management systems.
Notable trials will present data on tirzepatide in HFpEF, cardiac microcurrent therapy, and digital platforms for optimizing heart failure (搜索) treatment guidelines.
The Cardiovascular Research Foundation (CRF) has announced an extensive lineup of late-breaking clinical trials to be presented at the Technology & Heart Failure (搜索) Therapeutics (THT) 2025 conference, showcasing significant advances in heart failure treatment and management.
Innovative Surgical and Device-Based Therapies
The conference will open with groundbreaking research on robotic surgical techniques for heart transplantation, presented by Feras Khaliel. This session will also feature the 2-year results of the ALT FLOW trial, investigating left atrial to coronary sinus shunting in heart failure (搜索) patients with preserved ejection fraction, presented by Dr. Javed Butler.
A significant focus will be placed on mechanical support devices, with Dr. Gabriel Sayer presenting an analysis from the MOMENTUM 3 (搜索) trial examining right ventricular failure in patients with the HeartMate 3 LVAD. The FASTR trial, presented by Dr. James E. Udelson, will evaluate a novel approach to fluid management in acute decompensated heart failure (搜索) using the Reprieve Decongestion Management System.
Novel Therapeutic Approaches and Long-term Outcomes
Dr. Barry Borlaug will present crucial findings from the SUMMIT (搜索) trial, examining how obesity severity impacts the effectiveness of tirzepatide in heart failure (搜索) with preserved ejection fraction (HFpEF). The conference will also feature five-year outcome data from the REDUCE LAP-HF II (搜索) trial, presented by Dr. Sanjiv J. Shah, providing valuable long-term insights into atrial shunt treatment.
A particularly innovative study by Dr. Eduardo Rame will explore cardiac microcurrent application as a potential therapy for heart failure (搜索) reversal, representing a novel approach to treatment.
Digital Health and Quality Improvement Initiatives
The AIM-POWER (搜索) randomized controlled trial, presented by Dr. Akshay Desai, will showcase results from a digital platform designed to optimize guideline-directed heart failure (搜索) therapy, highlighting the growing role of technology in clinical care.
Advanced Mechanical Support and Surgical Outcomes
The final day will feature critical research on mechanical circulatory support, including an analysis from the Society of Thoracic Surgeons National Intermacs Database presented by Dr. Manreet Kanwar, examining the impact of preoperative temporary mechanical circulatory support on durable LVAD outcomes.
The RV Protection Study, presented by Dr. Anthony Kanelidis, will address strategies for preventing right ventricular dysfunction following left ventricular assist device implantation, a significant complication in advanced heart failure (搜索) therapy.